Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2019 / Cilt: 29 - Sayı: 2

Oncological Outcomes of Stage IIIA Endometrioid Type Endometrial Cancer: A Multicenter Study

Evre IIIA Endometrioid Tip Endometrial Kanserin Onkolojik Sonuçları: Retrospektif, Çok Merkezli Çalışma

Pages
88–96
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The five-year disease-free survival (DFS) rate was 57.2%, and the overall survival (OS) rate was 59.7%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The objective of this retrospective study was to evaluate Stage IIIA endometrioid type endometrial carcinomas (ECCs) and to analyzeclinical and pathological determinants of prognosis in three tertiary hospitals between January 2007 and January 2017.
📊
Key Findings & Data:Forty-sevenpatients with a median age of 61 (range: 31 to 76) years were diagnosed with Stage IIIA disease.
💡
Conclusion & Impact:The five-year disease-free survival (DFS) rate was 57.2%, and the overall survival (OS) rate was 59.7%.
🔬Design:Research Article
📍Scope:2007 Verileri
⚙️Variables:Domain Parameters

Abstract

The objective of this retrospective study was to evaluate Stage IIIA endometrioid type endometrial carcinomas (ECCs) and to analyzeclinical and pathological determinants of prognosis in three tertiary hospitals between January 2007 and January 2017. Forty-sevenpatients with a median age of 61 (range: 31 to 76) years were diagnosed with Stage IIIA disease. Median follow-up was 45 (range: 6 to116) months. The five-year disease-free survival (DFS) rate was 57.2%, and the overall survival (OS) rate was 59.7%. In the univariateanalysis, age and grade of the disease (1-2 versus 3) disease were found to be significant factors for DFS. Univariate analysis also revealed the presence of cervical stromal involvement and grade of the disease were associated with decreased OS. In the multivariateanalysis, however, only patients with an advanced histological grade had a reduced risk for OS (hazard ratio [HR] 2.9; 95% confidenceinterval [CI] 1.020-8.615; p= 0.040). In conclusion, histological grade seems to be an independent prognostic factor for OS in patientswith Stage IIIA ECCs.

Özet

Bu retrospektif çalışmada, Ocak 2007 – Ocak 2017 tarihleri arasında üç üniversite hastanesinde Evre IIIA endometrioid tip endometrial karsinomlar (EEK) değerlendirildi ve prognozun klinik ve patolojik belirleyicileri incelendi. Çalışmaya medyan yaşı 61 (dağılım: 31-76) yıl olan ve Evre IIIA hastalık ile tanılanan 47 hasta alındı. Medyan takip süresi 45 (dağılım: 6-116) ay idi. Beş yıllık hastalıksız sağkalım (DFS) oranı %57.2, genel sağkalım (OS) oranı %59.7 idi. Tek değişkenli analizde yaş ve hastalığın gradı (1-2 veya 3) DFS’yi etkileyen anlamlı faktörler olarak bulundu. Ayrıca, tek değişkenli analizde, servikal stromal tutulum ve hastalığın gradının azalmış OS süresi ile ilişkili olduğu tespit edildi. Bununla birlikte, çok değişkenli analizde, yalnızca ileri evre histolojik gradı olan hastalarda OS riskinde bir azalma görüldü (risk oranı [HR] 2.9; %95 güven aralığı [CI] 1.020-8.615; p= 0.040). Sonuç olarak, histolojik gradın Evre IIIA EEK’li hastalarda OS’nin bağımsız prognostik bir faktörü olduğu düşünülmektedir.

🔖

Cite This Article

SAHIN, H., YALCIN, I., SARI, M. E., SAHIN, E. A., ASLAN, K., AGLAMIS, O., GULSEREN, V., GUNGORDUK, K., MEYDANLI, M. M., AYHAN, A. (2022). Oncological Outcomes of Stage IIIA Endometrioid Type Endometrial Cancer: A Multicenter Study. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 29 - Sayı: 2, 88–96. https://ajindex.com/articles/644773

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Lortet-Tieulent J, Ferlay J, Bray F, et al. International Patterns and Trends in Endometrial Cancer Incidence 1978-2013. J Natl Cancer Inst 110: 354-361, 2018
  2. Lax SF. Pathology of Endometrial Carcinoma. Adv Exp Med Biol 943: 75-96, 2017
  3. Pecorelli S, Favalli G, Zigliani L, et al. Cancer in women. Int J Gynaecol Obstet 82: 369-379, 2003
  4. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105: 109, 2009
  5. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol 116: 1141-1149, 2010
  6. Mikuta JJ. International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 71: 1460-1463,1993
  7. Van Wijk FH, Huikeshoven FJ, Abdulkadir L, et al. Stage III and IV endometrial cancer: a 20-year review of patients. Int J Gynecol Cancer 16: 1648-1655, 2006
  8. Li QS, Li DP, Wu XR, et al. Surgical treatment in advanced endometrial carcinoma. Zhonghua Fu Chan Ke Za Zhi 44: 750-753, 2009
  9. Sari ME, Meydanli MM, Turkmen O, et al. Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study. J Gynecol Oncol 28: e49, 2017
  10. Havrilesky LJ, Cragun JM, Calingaert B, et al. The prognostic significance of positive peritoneal cytology and adnexal/ serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 104: 401-405, 2007
  11. Denschlag D, Tan L, Patel S, et al. Stage III endometrial cancer: preoperative predictability, prognostic factors, and treatment outcome. Am J Obstet Gynecol 196: 546 e1-7, 2007
  12. Mariani A, Webb MJ, Keeney GL, et al. Assessment of prognostic factors in stage IIIA endometrial cancer. Gynecol Oncol 86: 38-44, 2002
  13. Preyer O, Obermair A, Formann E, et al. The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer. Gynecol Oncol 86: 269-273, 2002
  14. Wethington SL, Barrena Medel NI, Wright JD, et al. Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol 115: 18-25, 2009
  15. Cooke EW, Pappas L, Gaffney DK. Does the revised International Federation of Gynecology and Obstetrics staging system for endometrial cancer lead to increased discrimination in patient outcomes? Cancer 1